Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.
Follow GYRE
Gyre Therapeutics, Inc. (GYRE) EV/Sales
As of 16 October 2026, Gyre Therapeutics, Inc. (GYRE) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from −75.1× (June 2018) to 161× (April 2018); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.7× | (51.11%) |
| FY2024 | 9.5× | (29.67%) |
| FY2023 | 13.6× | 167.28% |
| FY2022 | 5.1× | — |
| FY2021 | −1.9× | — |
| FY2020 | 2.2× | — |
| FY2018 | −35.1× | — |
| FY2017 | 16.4× | — |
| FY2016 | −23.2× | — |
| FY2015 | −10.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.1× | 0.84% |
| Mar 2026 | 5.1× | 8.50% |
| Dec 2025 | 4.7× | (17.53%) |
| Sep 2025 | 5.7× | (1.92%) |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AURA Aura Biosciences, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR compare | 1.2× |
| MDXG MiMedx Group, Inc compare | 1.5× |
| GYRE Gyre Therapeutics, Inc. | 4.7× |
| OABI OmniAb, Inc. compare | 14.0× |
| PRME Prime Medicine, Inc. compare | 128× |
| DSGN Design Therapeutics, Inc. compare | 1,934× |
| CADL Candel Therapeutics, Inc. compare | 3,661× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)